Direct Impact

Concepts for which Chloé Charloteaux has direct influence:

invasive lobular
endocrine therapy
breast cancer
targeting ros1
carcinoma ilbc
inhibitors combination

Prominent publications by Chloé Charloteaux

KOL-Index: 2 Despite different clinical characteristics including the response to treatment and the patterns of metastatic relapse, invasive lobular breast carcinoma (ILBC) is treated like invasive ductal breast carcinoma (IDBC) carcinoma both in the clinics and in clinical trials. A large majority of ILBC are ER+/HER2- and almost 90% have loss of E-cadherin (CDH1) expression. A non-clinical study of ...
Known for
Her2 Metastatic | Idbc Ilbc | Ductal Breast | Letrozole Combination

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172